Researchers analyzed side effects reported by V-SAFE participants who received the Pfizer or Modern Vaccine between December 14, 2020 and February 28, 2021. She focused on 35,691 participants who stated that she was pregnant when she was pregnant. Subsequently, she became vaccinated or pregnant.
After vaccination, pregnant participants reported the same general pattern of side effects that non-active people did, the researchers found: pain, fatigue, headaches, and muscle aches at the injection site.
- On April 13, 2021, US health agencies called for an immediate halt in the use of Johnson & Johnson’s single-dose Kovid-19 vaccine after six recipients in the United States received blood within one to three weeks of vaccination. A rare disorder associated with clots developed.
- All 50 states, Washington DC And Puerto Rico temporarily prohibits or recommends providers stop the use of the vaccine. The US military jointly runs the vaccination site, and a host of private companies, including CVS, Walgreens, Reit Aid, Walmart, and Publix, also stopped the injection.
- More than one less in Johnson & Johnson vaccination is now under investigation. If there is indeed a risk of blood clots from the vaccine – which has not yet been determined – then this risk is extremely low. The risk of acquiring Kovid-19 is far greater in the United States.
- The stagnation can complicate the nation’s vaccination efforts at a time when many states are experiencing an increase in new cases and are trying to overcome vaccine inhibition.
- Johnson & Johnson had also decided to delay the rollout of its vaccine in Europe amid concerns over rare blood clots, but the EU drug regulator later said the warning label should be added. South Africa, devastated by a more contagious virus type that emerged there, suspended the use of the vaccine and Australia announced it would not buy any of the supplements.
Women who were pregnant were slightly more likely to report injection site pain than women who were unlikely to report other side effects. They were slightly more likely to report nausea or vomiting after the second dose.
Pregnant V-SAFE participants were also given the opportunity to enroll in a special registry that monitors pregnancy and child outcomes.
By the end of February, 827 of those enrolled in the pregnancy registry had completed their pregnancies, with 86 percent of those born alive. According to the researchers’ report, rates of miscarriage, premature birth, low birth weight and birth defects were consistent among pregnant women.
“This study is of critical importance to pregnant individuals,” said Dr., a maternal-fetal medicine specialist at the University of Pennsylvania. Michael Elowitz said in an email. “It is very reassuring that no acute events occurred in pregnant individuals during the study”, he said.
But the report has several limitations and requires much research, experts said. Enrollment in monitoring programs is voluntary and data are self-reported.